Clinical Impact of Pitolisant on Excessive Daytime Sleepiness and Cataplexy in Adults With Narcolepsy: An Analysis of Randomized Placebo-Controlled Trials.

Autor: Meskill GJ; Tricoastal Narcolepsy and Sleep Disorders Center, Sugar Land, TX, USA. gmeskillmd@tricoastalsleep.com., Davis CW; Harmony Biosciences, LLC, Plymouth Meeting, PA, USA., Zarycranski D; Harmony Biosciences, LLC, Plymouth Meeting, PA, USA., Doliba M; Harmony Biosciences, LLC, Plymouth Meeting, PA, USA., Schwartz JC; Bioprojet Pharma, Paris, France., Dayno JM; Harmony Biosciences, LLC, Plymouth Meeting, PA, USA.
Jazyk: angličtina
Zdroj: CNS drugs [CNS Drugs] 2022 Jan; Vol. 36 (1), pp. 61-69. Date of Electronic Publication: 2021 Dec 21.
DOI: 10.1007/s40263-021-00886-x
Abstrakt: Background: Pitolisant, a selective histamine 3 receptor antagonist/inverse agonist, is indicated for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The efficacy and safety of pitolisant have been demonstrated in randomized placebo-controlled trials. When evaluating the results of randomized placebo-controlled trials, the clinical impact of a treatment can be assessed using effect size metrics that include Cohen's d (the standardized mean difference of an effect) and number needed to treat (NNT; number of patients that need to be treated to achieve a specific outcome for one person).
Objective: The objective of this study was to evaluate the clinical impact of pitolisant for the reduction in excessive daytime sleepiness or cataplexy in adults with narcolepsy.
Methods: This post hoc analysis incorporated data from two 7-week or 8-week randomized placebo-controlled trials (HARMONY 1, HARMONY CTP). Study medication was individually titrated, with a maximum possible pitolisant dose of 35.6 mg/day. Efficacy was assessed using the Epworth Sleepiness Scale (ESS) and weekly rate of cataplexy (HARMONY CTP only). Cohen's d was derived from the least-squares mean difference between treatment groups (pitolisant vs placebo), and NNTs were calculated from response rates. Treatment response was defined for excessive daytime sleepiness in two ways: (a) reduction in ESS score ≥ 3 or final ESS score ≤ 10 and (b) final ESS score ≤ 10. Treatment response was defined for cataplexy as a ≥ 25%, ≥ 50%, or ≥ 75% reduction in weekly rate of cataplexy.
Results: The analysis population included 61 patients in HARMONY 1 (pitolisant, n = 31; placebo, n = 30) and 105 patients in HARMONY CTP (pitolisant, n = 54; placebo, n = 51). For pitolisant vs placebo, Cohen's d effect size values were 0.61 (HARMONY 1) and 0.86 (HARMONY CTP) based on changes in ESS scores, and 0.86 (HARMONY CTP) based on changes in weekly rate of cataplexy. NNTs for pitolisant were 3-5 for the treatment of excessive daytime sleepiness and 3-4 for the treatment of cataplexy.
Conclusions: The results of this analysis demonstrate the robust efficacy of pitolisant for the reduction in both excessive daytime sleepiness and cataplexy. These large effect sizes and low NNTs provide further evidence supporting the strength of the clinical response to pitolisant in the treatment of adults with narcolepsy.
Clinical Trial Registration: ClinicalTrials.gov identifiers: NCT01067222 (February 2010), NCT01800045 (February 2013).
(© 2021. The Author(s).)
Databáze: MEDLINE
Externí odkaz: